Pacific Biosciences
PACB
88 hedge funds and large institutions have $178M invested in Pacific Biosciences in 2014 Q3 according to their latest regulatory filings, with 15 funds opening new positions, 30 increasing their positions, 26 reducing their positions, and 13 closing their positions.
24% more call options, than puts
Call options by funds: $409K | Put options by funds: $331K
15% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 13
15% more repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 26
2% more funds holding
Funds holding: 86 → 88 (+2)
23% less capital invested
Capital invested by funds: $230M → $178M (-$52.9M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MOACM
Mutual of America Capital Management
New York
|
+$2.17M |
| 2 |
Goldman Sachs
New York
|
+$1.68M |
| 3 |
Connor, Clark & Lunn Investment Management (CC&L)
Vancouver,
British Columbia, Canada
|
+$1.19M |
| 4 |
OIM
Oracle Investment Management
Greenwich,
Connecticut
|
+$1.17M |
| 5 |
D.E. Shaw & Co
New York
|
+$889K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$5.26M |
| 2 |
Invesco
Atlanta,
Georgia
|
-$2.2M |
| 3 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
-$2.05M |
| 4 |
DM
Deerfield Management
New York
|
-$1.55M |
| 5 |
IG
ING Group
Amsterdam,
Netherlands
|
-$1.54M |
PACB Hedge Fund Activity: Q3 2014 in Review
88 of the 3,446 institutional investors tracked by Wall St. Rank reported a position in Pacific Biosciences (PACB) for Q3 2014, worth a combined $178M — down 23% from $230M a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new PACB positions and 13 closed out — a net gain of 2 holders — while 30 added to existing stakes and 26 trimmed.
The largest buyer was Mutual of America Capital Management, opening a new position worth an estimated $2.17M. The largest seller was Millennium Management, cutting an estimated $5.26M.
- 88 institutional investors held Pacific Biosciences (PACB) as of Q3 2014, up from 86 in Q2 2014.
- Funds reported $178M of Pacific Biosciences stock for Q3 2014, down 23% quarter-over-quarter.
- 15 funds opened new Pacific Biosciences positions in Q3 2014 and 13 closed out, a net change of +2 holders.
- The largest Pacific Biosciences buyer in Q3 2014 was Mutual of America Capital Management, an estimated $2.17M added.
- The largest Pacific Biosciences seller in Q3 2014 was Millennium Management, an estimated $5.26M sold.
Based on aggregated 13F filings for Q3 2014.